Literature DB >> 18210015

[CA 19-9 in the differential diagnosis of pancreatic lesions].

S Stintzing1, C Herold, E G Hahn, F Boxberger.   

Abstract

CA 19-9 is still used in the differential diagnosis of pancreatic lesions. As it has been shown to be elevated in many other non-pancreatic diseases--sometimes even extraordinarily--this marker should not be used to set the diagnosis of a pancreas carcinoma anymore. Especially if there is a concomitant cholestasis there is no diagnostic value to perform the measurement of CA 19-9. As the histological confirmation is the only way to get the exact diagnosis endoscopic ultrasound guided fine-needle aspiration biopsy should be considered in lesions of the pancreatic head.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18210015     DOI: 10.1007/s00108-007-1993-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  11 in total

Review 1.  Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level.

Authors:  Javier L Parra; Steven Kaplan; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

2.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

3.  Pancreatic FNA in 1000 cases: a comparison of imaging modalities.

Authors:  Keith E Volmar; Robin T Vollmer; Paul S Jowell; Rendon C Nelson; H Bill Xie
Journal:  Gastrointest Endosc       Date:  2005-06       Impact factor: 9.427

4.  CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.

Authors:  V Heinemann; M M Schermuly; P Stieber; L Schulz; D Jüngst; R Wilkowski; A Schalhorn
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

5.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Authors:  D V Mann; R Edwards; S Ho; W Y Lau; G Glazer
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

Review 6.  [CA19-9 has no value as a tumor marker in obstructive jaundice].

Authors:  R Peterli; B Meyer-Wyss; U Herzog; P Tondelli
Journal:  Schweiz Med Wochenschr       Date:  1999-01-23

7.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

8.  Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

Authors:  H Jalanko; P Kuusela; P Roberts; P Sipponen; C A Haglund; O Mäkelä
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

9.  Fine-needle aspiration biopsy of pancreatic ductal adenocarcinoma: loss of diagnostic accuracy with small tumors.

Authors:  R A Graham; M Bankoff; R Hediger; H Z Shaker; R B Reinhold
Journal:  J Surg Oncol       Date:  1994-02       Impact factor: 3.454

Review 10.  Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature.

Authors:  M Akdoğan; N Saşmaz; B Kayhan; I Biyikoğlu; S Dişibeyaz; B Sahin
Journal:  Tumori       Date:  2001 Sep-Oct
View more
  1 in total

Review 1.  [Pancreatic carcinoma].

Authors:  M P Lutz; S Pourebrahim
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.